ODI Pharma has been approved for listing on Spotlight Stock Market – subscription period in the new share issue starts today
ODI Pharma AB (“ODI Pharma” or “the Company”), a medical cannabis finished product producer, today announces that the Company has been approved for listing on Spotlight Stock Market (“Spotlight”). The listing is approved provided that the lowest limit in the upcoming new share issue is reached and the marketplace’s dilution requirements are met. ODI Pharma also announces that the subscription period in the Company’s new share issue commences today, the 16th of December 2019. The subscription period ends on the 30th of December 2019. At a fully subscribed new share issue the Company will